Atrial fibrillation in older inpatients: are there any differences in clinical characteristics and pharmacological treatment between the frail and the non-frail?

被引:42
|
作者
Nguyen, T. N. [1 ,2 ,3 ,4 ]
Cumming, R. G. [4 ]
Hilmer, S. N. [1 ,2 ,3 ]
机构
[1] Univ Sydney, Royal N Shore Hosp, Dept Clin Pharmacol, Sydney, NSW 2006, Australia
[2] Univ Sydney, Royal N Shore Hosp, Dept Aged Care, Sydney, NSW 2006, Australia
[3] Univ Sydney, Sydney Med Sch, Kolling Inst Med Res, Sydney, NSW 2006, Australia
[4] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia
关键词
atrial fibrillation; frailty; anticoagulant; anti-arrhythmic; stroke; bleeding; ANTICOAGULATION THERAPY; ANTITHROMBOTIC THERAPY; ORAL ANTICOAGULATION; MAJOR HEMORRHAGE; HEART-FAILURE; HIGH-RISK; WARFARIN; STROKE; DIGOXIN; IMPACT;
D O I
10.1111/imj.12912
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundFrailty is common in patients with atrial fibrillation and may impact on antithrombotic and anti-arrhythmic treatment. AimTo describe differences in clinical characteristics, prescription of antithrombotic and anti-arrhythmic medications and incidence of haemorrhage and stroke, between frail and non-frail older inpatients. MethodsProspective observational study in patients aged 65years with atrial fibrillation admitted to a teaching hospital in Sydney, Australia. Frailty was assessed using the Reported Edmonton Frail Scale, stroke risk with CHA2DS2-VASc score and bleeding risk with HAS-BLED score. Participants were followed after 6months for haemorrhages and strokes. ResultsWe recruited 302 patients (mean age 84.7 7.1years, 53.3% frail, 50% female, mean CHA2DS2-VASc 4.61 +/- 1.44, mean HAS-BLED 2.97 +/- 1.04). Frail participants were older and had more co-morbidities and higher risk of stroke but not haemorrhage. Upon discharge, 55.7% participants were prescribed with anticoagulants (49.3% frail, 62.6% non-frail, P = 0.02). Thirty-three per cent received antiplatelets only and 11.1% no antithrombotics, with no difference by frailty status. For anti-arrhythmics, 52.6% received rate-control drugs only, 11.8% rhythm-control drugs only and 13.5% both and 22.1% were not prescribed either, with no difference by frailty status. On univariate logistic regression, frailty decreased the likelihood of anticoagulant prescription (odds ratio (OR) 0.58, 95%CI 0.36-0.93), but this was not significant on multivariate analysis (OR 0.66, 95%CI 0.40-1.11). After 6months, overall incidence of ischaemic stroke was 2.1%, and in patients taking anticoagulants, incidence of major/severe bleeding was 6.3%, with no significant difference between frailty groups. ConclusionsFrailty status had little impact on antithrombotic prescription and no impact on anti-arrhythmic prescription.
引用
收藏
页码:86 / 95
页数:10
相关论文
共 47 条
  • [31] Non-Pharmacological, Non-Ablative Approaches for the Treatment of Atrial Fibrillation: Experimental Evidence and Potential Clinical Implications
    Scherlag, Benjamin J.
    Nakagawa, Hiroshi
    Jackman, Warren M.
    Lazzara, Ralph
    Po, Sunny S.
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2011, 4 (01) : 35 - 41
  • [32] Non-Pharmacological, Non-Ablative Approaches for the Treatment of Atrial Fibrillation: Experimental Evidence and Potential Clinical Implications
    Benjamin J. Scherlag
    Hiroshi Nakagawa
    Warren M. Jackman
    Ralph Lazzara
    Sunny S. Po
    Journal of Cardiovascular Translational Research, 2011, 4 : 35 - 41
  • [33] Letter by Ko et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"
    Ko, Darae
    Kim, Dae Hyun
    Singer, Daniel E.
    CIRCULATION, 2024, 150 (02) : e25 - e26
  • [34] Letter by Suwa et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"
    Suwa, Michihiro
    Morii, Isao
    Kino, Masaya
    CIRCULATION, 2024, 150 (02) : e27 - e27
  • [35] Letter by Kohsaka et al Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"
    Kohsaka, Shun
    Nishimura, Shiori
    Kumamaru, Hiraku
    CIRCULATION, 2024, 150 (02) : e28 - e29
  • [36] Clinical and cardiac structural differences between paroxysmal and persistent/permanent non-valvular atrial fibrillation
    Bhat, A.
    Chen, H. H. L.
    Khanna, S.
    Gan, C. H.
    Menzies, R.
    Nunes, C. M.
    MacIntyre, R.
    Tan, T. C.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1434 - 1434
  • [37] Response by van Doorn et al to Letters Regarding Article, "Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial"
    van Doorn, Sander
    Rutten, Frans H.
    Geersing, Geert-Jan
    CIRCULATION, 2024, 150 (02) : e30 - e32
  • [38] Differences in Clinical Characteristics and Outcomes between Patients with Paroxysmal and Sustained Type of Atrial Fibrillation: From the Fushimi Af Registry
    Takabayashi, Kensuke
    Unoki, Takashi
    Ogawa, Hisashi
    Iguchi, Moritake
    Esato, Masahiro
    Chun, Yeong-Hwa
    Wada, Hiromichi
    Hasegawa, Koji
    Abe, Mitsuru
    Akao, Masaharu
    CIRCULATION, 2013, 128 (22)
  • [39] Differences in clinical characteristics and treatment in hepatocellular carcinoma between Asians and non-Asians
    Wong, Kit Man
    Lee, Jonghun John
    Wong, Amy
    Liu, Geoffrey
    Sherman, Morris
    Cleary, Sean P.
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [40] Clinical characteristics of apixaban prescription in AF patients with single dose-reduction criterion: the ASPIRE (efficAcy and safety of aPixaban in rEal-world practice in Korean frail patients with atrial fibrillation) study
    Choi, Jungmin
    Lee, So-Ryoung
    Kwon, Soonil
    Ahn, Hyo-Jeong
    Lee, Kyung-Yeon
    Park, Jong-Sung
    Choi, Jong-Il
    Lee, Sung Ho
    Heo, Jung Ho
    Oh, Il-Young
    On, Young Keun
    Yu, Hee Tae
    Lee, Kwang-No
    Kim, Nam-Ho
    Park, Hyung Wook
    Lee, Ki Hong
    Shin, Seung Yong
    Oh, Seil
    Lip, Gregory Y. H.
    Han, Seongwook
    Choi, Eue-Keun
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11